Related Experiment Video
Updated: Jul 28, 2026
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Reduced Plasma miR-146a Is a Predictor of Poor Coronary Collateral Circulation in Patients with Coronary Artery
Junnan Wang1, Youyou Yan1, Dandan Song2
1Department of Cardiology, Second Hospital of Jilin University, No. 218 Ziqiang Street, Changchun 130041, China.
Insights
Plasma microRNA-146a (miR-146a) levels can differentiate coronary artery disease (CAD) patients with good or poor coronary collateral circulation (CCC). Elevated miR-146a indicates good CCC, while decreased levels suggest poor CCC in CAD patients.
Area of Science:
- Cardiology
- Molecular Biology
- Biomarker Discovery
Background:
- Coronary artery disease (CAD) patients benefit from coronary collateral circulation (CCC).
- Lack of reliable biomarkers hinders the assessment of CCC in CAD.
- MicroRNAs are implicated in cardiovascular disease pathogenesis.
Purpose of the Study:
- To investigate the relationship between plasma microRNA-146a (miR-146a) and coronary collateral circulation (CCC) in CAD patients.
- To evaluate miR-146a as a potential blood-based biomarker for CCC in CAD.
Main Methods:
- Plasma miR-146a and VEGF-A levels were measured using real-time PCR and ELISA, respectively.
- Patients were categorized based on Rentrop grading for CCC assessment.
- Correlations between miR-146a levels and Rentrop grades were analyzed.
Main Results:
- Plasma miR-146a levels were significantly higher in CAD patients with good CCC and lower in those with poor CCC.
- A positive correlation was observed between plasma miR-146a levels and Rentrop grading.
- VEGF-A showed a similar trend but without statistical significance between groups.
Conclusions:
- Plasma miR-146a is significantly associated with the degree of coronary collateral circulation in CAD patients.
- miR-146a demonstrates potential as a diagnostic biomarker for identifying poor CCC in CAD.
- Further research is warranted to validate miR-146a as a clinical tool for CCC assessment.
Abstract:
Coronary collateral circulation (CCC), an alternative blood supply for ischemic myocardium, improves survival rates among patients with coronary artery disease (CAD). However, there remains a lack of biomarkers to discriminate between patients with poor or good CCC. In this study, we aimed to observe the relationship between plasma microRNA-146a (miR-146a) levels and the coronary collateral circulation (CCC). Additionally, we aimed to explore whether the plasma miR-146a level could serve as a blood-based biomarker for CCC in patients with CAD. We measured the plasma levels of vascular endothelial growth factor A (VEGF-A) and miR-146a in patients with CCC by ELISA and real-time PCR, respectively, according to the Rentrop grades. The results showed that the plasma miR-146a level is significantly increased in CAD patients with good CCC and significantly decreased in those with poor CCC. In contrast, although VEGFA expression in patients followed a similar trend as the CCC, the differences between the groups were not statistically significant. There was a positive correlation between plasma miR-146a levels and the Rentrop grading. In addition, receiver operator characteristic analysis showed that miR-146a could be a potent biomarker for identifying patients with poor CCC.
More Related Videos
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
